Oryzon Genomics S.A.
ORYZF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $7 | $14 | $16 | $11 |
| % Growth | -48.1% | -9.6% | 47.9% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $1 |
| Gross Profit | $7 | $14 | $15 | $10 |
| % Margin | 95.9% | 98.3% | 97% | 93% |
| R&D Expenses | $6 | $6 | $7 | $7 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $4 | $4 | $4 | $4 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $2 | $9 | $11 | $6 |
| Operating Expenses | $11 | $18 | $21 | $17 |
| Operating Income | -$4 | -$5 | -$5 | -$7 |
| % Margin | -60.1% | -32.1% | -35% | -66% |
| Other Income/Exp. Net | -$1 | -$2 | -$1 | -$0 |
| Pre-Tax Income | -$6 | -$6 | -$7 | -$7 |
| Tax Expense | -$2 | -$3 | -$2 | -$2 |
| Net Income | -$4 | -$3 | -$4 | -$5 |
| % Margin | -49.8% | -23.6% | -27% | -44.2% |
| EPS | -0.057 | -0.055 | -0.076 | -0.089 |
| % Growth | -2.7% | 27% | 15% | – |
| EPS Diluted | -0.057 | -0.055 | -0.076 | -0.089 |
| Weighted Avg Shares Out | 65 | 61 | 56 | 53 |
| Weighted Avg Shares Out Dil | 65 | 61 | 56 | 53 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $1 | $2 | $1 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$4 | -$4 | -$5 | -$7 |
| % Margin | -59.5% | -31.2% | -34.1% | -64.8% |